INTRODUCTION
The commonest form of autoimmune hemolytic anemia is characterized by the presence of antibody of the IgG immunoglobulin class on the red cell (1) . These antibodies characteristically react with red cell antigens at body temperature, and they fix complement relatively inefficiently since two antibody molecules in juxtaposition are required to initiate a complement sequence (2) .
The exact mechanism by which the red cells are destroyed in this syndrome is not completely understood.
Recently it has been demonstrated that the presence of the IgG antibody on the surface of the red cell may cause it to adhere to monocytes and splenic macrophages (3, 4) . In this reaction, a portion of the red cell memReceived for publication 20 July 1970 and in revised form 7 December 1970. brane may be removed, resulting in spherocytosis. Sequestration of the cells by elements of the reticuloendothelial system, especially the spleen, is probably responsible for the ultimate destruction of the cells. When complement is fixed, direct cytolysis may account for a small part of the cellular destruction. The rate of hemolysis in patients with hemolytic anemia due to warm-reacting antibody may vary greatly, and a relationship between the degree of anemia or the rate of hemolysis and the amount of antibody on the red cell surface has been suspected but has not been established (5, 6) . The investigation of this relationship has been hampered by the difficulty in determining the amount of antibody on the cells and in the serum of patients with this disease. The amount of antibody on the cell has been estimated by elution (7) , with radiolabeled antiglobulin (6) and, more recently, by an indirect estimate of the amount of anti-IgG which adheres to cells coated with IgG (8) .
In the present studies, we have undertaken to estimate the amount of antibody present on the red cell surface by measuring the fixation of the first component of complement, C1. Since IgG autoimmune antibodies fix complement only very poorly, if at all, we have reacted IgGcoated cells with rabbit anti-IgG. The combination of two anti-globulin molecules brings about the fixation of a C1 molecule (9) . The concentration of anti-globulin can be adjusted so that the direct proportion exists between the number of Cl molecules fixed and the number of IgG autoimmune antibody molecules present on the red cell. By this method, we are able to derive a minimum but proportional estimate of the number of antibody molecules present on the surface of the red cell.
The rate of hemolysis in these patients was measured by a modification' of the endogenous carbon monoxide method of Coburn, Williams, and Kahn (10) . This method was chosen since frequent serial estimates of the red cell survival time were needed in order to follow the effect of therapy. Using these methods, we have investigated the effect of antibody coating of the red cells, the effect of splenectomy in these patients, and the effects of adrenocortical steroid therapy.
METHODS
Patients. 30 patients with autoimmune hemolytic anemia, warm antibody type, in whom the direct anti-globulin test (Coombs test) was positive using anti-IgG antiserum, and in whom the amount of IgG on the cells could be quantitated by the methods described below, were studied. A summary of the clinical course and laboratory data of these patients mentioned specifically in the text are given in Table I cysteine-activated papain, at pH 7.4 for 20 min. After incubation, the cells were washed twice and resuspended in the original volume of 60% VBS-sucrose buffer.
Red cell survival time. Red cell survival time was measured by the endogenous production of carbon monoxide, by use of a gas phase analytic system described by Logue et al. The red cell life span estimated from carbon monoxide was calibrated with the red cell life span determined by the diisopropylflourophosphate (DFP3) method of Cline and Berlin (14) . The values expressed are for the corrected mean red cell life span; normal is 100-130 days.
RESULTS
Relationship between hemolytic rate and cell-bound antibody. The amount of cell-bound antibody was determined in 25 patients with immune hemolytic anemia, warm antibody type, before treatment with steroids, splenectomy, or immunosuppressive agents. The relation- 3) . In eight patients, the amount of cell-bound antibody was measured before and after the onset of a hemolytic exacerbation (Table II) . These data indicate that the main determinant for the rate of destruction of red cells in warm antibody hemolytic anemia is the amount of cellbound antibody. tients who had not been splenectomized. However, heCount molysis occurred when he amount of cell-bound antibody became excessive (Fig. 4, Table II , patients A. G. and R. F.). One patient, M. P., was extensively studied be-D0 fore and after splenectomy (Fig. 5) . The increased tolerance for cell-bound antibody after splenectomy is clearly shown.
In five patients, the amount of antibody attached to red cells extruded from the spleen at operation was compared to the amount present in the peripheral blood on 0 the same day (Table III) . In each case, the amount of 00 ooantibody on the red cells from splenic blood exceeded that present on the red cells in the peripheral blood.
The effect of predisone therapy. 15 patients were 0 given 60 mg of prednisone per day at the beginning of therapy. In 10 patients, the amount of antibody present on the cells fell rapidly In eight of these patients, this 12 13 rapid dimunition of the cellbound antibody was accompanied by an increase in the amount of antibody present in concentra-in the serum. When tested, the mean red cell life span ation of cell-was seen to increase as the amount of antibody decreased rgone splenec-(see Figs. 6 and 7) . This effect appears to be a function nt was taking of the high dose of prednisone given since, in patient =rminations. R. A. at day 20, when the dosage of prednisone was reduced from 60 mg/day, the amount of antibody present ship between on the cell began to increase and the amount of antibody emolytic rate in the serum to decrease. When the dose of prednisone roduction or was again raised to 60 mg/day on day 25, the cell-bound six patients antibody again decreased (see Fig. 7 ). d 2). These In five patients, the rapid removal of cell-bound anti-*e i for body was not accompanied by an increase in the antibody iemolysis for ody than pa-cell-bound in the serum (Fig. 8) . In three patients, the amount of cell-bound antibody diminished only slowly over a period of 10-20 days. In one patient, prednisone ount appeared to be virtually without effect on the concentration of cell-bound antibody. This patient did not have a remission in hemolytic rate as judged by a decreased hematocrit and continued transfusion requirement.
14 FIGURE 5
The relationship between the concentration of hemoglobin in peripheral blood and the concentration of cell-bound antibody in patient M. P. before and after splenectomy. (Table IV) . This effect was seen in all patients undergoing clinical remission with prednisone treatment. The time required for the concentration in serum antibody to reach low levels ranged from 4 to 87 days. This time period appeared to be longer for patients with chronic lymphocytic leukemia than for patients not having this disease.
Once the amount of antibody present in the serum had fallen, prednisone dosage could be safely reduced to levels of less than 10 mg/100 ml in all patients achieving this response. Three patients did not have a marked dimunition in the amount of antibody present in the serum. In these patients, the amount of antibody on the cells, the amount of antibody in the serum, and the hemolytic rate remained high.
A third effect of prednisone was deduced from analysis of the results of patient R. A. (see Fig. 6 ). In this patient, the amount of cell-bound antibody present on day 20 was approximately that present before the onset of prednisone therapy. However, the mean red cell life span was approximately four times the initial value. This suggests that prednisone may interfere with the sequestration of the antibody-coated red cells by the reticuloendothelial system. The quantitative relationship between the amount of antibody present on the cell surface and the rate of destruction of the cells has been somewhat obscure in the past. Jandl and Kaplan showed D-positive red cells sensitized with anti-D and injected into normal recipients were rapidly destroyed (15) . The rate of destruction was roughly parallel to the amount of antibody used in sensitization. These findings were confirmed and expanded by the studies of Mollison, Crome, Hughes-Jones, and Rochna (5). These investigators used much higher concentrations of antibody and observed much more rapid rates of red cell destruction. Constantoulakis, Costea, Schwartz, and Dameshek measured the amount of antibody on the red cells of patients with autoimmune hemolytic anemia using an antiIgG labeled with 'I and sought to relate the level of antibody to the red cell life span as measured by 51Cr (6) .
Although they could demonstrate with a single example of anti-D that the amount of antibody on cells sensitized in vitro was related to their life span, they found no relationship between the amount of antibody coating and destruction rate in patients with immune hemolytic anemia. They attributed this lack of correlation to variability in the avidity of antibody for the red cell or to factors other than concentration of antibody.
The present studies suggest that the concentration of antibody bound to the red cell is, in fact, a prime determinant of the red cell survival time in these patients. Although there was considerable variation among the patients studied, those who were most anemic at presentation and/or who had the greatest production of endogenous carbon monoxide as a measure of heme destruction were those whose red cells were most heavily coated with antibody. This appears to be so whether or not the antibody was capable of fixing complement. In individual patients studied serially, the red cell life span was, in general, inversely related to the amount of antibody present on the red cell. When hematologic relapse occurred, the concentration of antibody on the cells was invariably increased above levels present during remission, and when remission occurred, the amount of antibody was lower in nearly all instances than during the hemolytic episode.
The mechanism by which the presence of antibody on the cell surface brings about the destruction of the cell is not at all certain. Archer (3) and Lo Buglio, Cotran, and Jandl (4) found that antibody-coated cells were adherent to the monocytes or splenic macrophages. This appeared to result in engulfment or loss on the part of the membrane resulting in spherocytes. This adherence phenomenon appears to be a function of the IgG molecule since none of the other immunoglobulins or complement appear to be able to effect this reaction. This phenomenon appears to be different from erythrophagocytosis since polymorphonuclear leukocytes cannot engulf IgG antibody-coated cells in the absence of complement (16) . From the present studies, it appears that the greater the number of IgG molecules coating the cell, the greater likelihood that the cells will adhere to macrophages of the reticuloendothelial system.
The data on cells extruded from the spleen might indicate that more heavily sensitized cells were sequestered preferentially by the spleen. However, the increase in cell-bound antibody on these cells might also be due to local production of antibody in splenic cells.
The spleen is of paramount importance in the process of destruction of the red cells in patients with IgG warm agglutinin disease. Removal of the spleen reduces the rate of hemolysis in many patients. The data from the patients studied here suggests that when the spleen is removed, up to 10 times as much antibody must be present on the red cell to effect the same degree of lysis. This would suggest that the other sites of attachment of IgG-coated cells within the reticuloendothelial system were less efficient than splenic sites. When, however, the concentration of antibody on the cell reaches a sufficient concentration, sequestration does occur and the hemolysis results, despite the absence of the spleen.
These findings corroborate single studies by Constatoulakis et al. (6) and by Jandl and Kaplan (15) . The former group found that cells from a patient with immune hemolytic anemia survived longer in a splenectomized patient than in an unsplenectomized patient. Jandl and Kaplan found that more antibody had to be added to cells in vitro in order to obtain the same rate of red cell destruction in a splenectomized patient compared to an unsplenectomized patient.
Days FIGURE 8 The changes in cell-bound and serum antibody concentration, hemoglobin concentration, and reticulocyte count after prednisone therapy in patient B. B.
The adrenocortical steroids have been known for at least 20 yr to induce remission in patients with autoimmune hemolytic anemia of the warm antibody type (17) . Three mechanisms were proposed for the effect: (a) dimunition of antibody production (18), (b) dimunition of sequestration (19) , and (c) alteration of the red cell- (20) . Without the quantitative methods used in these studies, it has been very difficult to test these hypotheses in patients. Certainly, in experimental animals, it is possible to demonstrate dimunition of antibody production after treatment with steroids, especially IgG antibody of the secondary immune reaction (18, 21, 22) . Using dilution techniques, Evans, Bingham, and Boehni, among others, have found that the amount of serum antibody decreased during prednisone therapy in patients with autoimmune hemolytic anemia (18) . The present studies demonstrate that the total amount of antibody (cell bound + serum) is usually decreased after prednisone therapy. The time interval between the initiation of prednisone therapy and the reduction in serum antibody varies from 4 to 90 days. This interval tended to be longer in patients with chronic lymphocytic leukemia and reduction in serum antibody sometimes did not occur until the leukemic process was brought under control by other chemotherapeutic agents. If the reduction in serum antibody did not occur, remission was difficult to obtain and maintain. This reduction in serum antibody, when it did occur, could usually be maintained by relatively small doses of prednisone (10 mg or less per day). If the dose was reduced too far, the amount of antibody in the serum rose as did the amount of cell-bound antibody and increased hemolysis occurred (see Fig. 7 ). Clearly the dimunition in total concentration (serum + cell bound) is probably the most important effect of prednisone; how it is brought about is unknown.
An effect of prednisone in decreasing sequestration may also be inferred from these data. In patient R. A., the mean red cell life span was longer for the same or greater doses of cell-bound antibody when prednisone was given than before the initiation of that therapy. This effect of prednisone has been postulated by Kaplan and Jandl in studies on rats injected with antibodycoated cells (19) . They found that prednisone decreased the sequestration of cells in the reticuloendothelial system other than the spleen. The present data do not allow determination of the importance of this effect of steroids nor localization of the effect to any part of the reticuloendothelial system.
Prednisone may alter the affinity of antibody for the red cell. In more than half the patients studied, the amount of antibody on the cells fell rapidly and the amount in the serum rose upon the initiation of high doses of the drug. Where measured, the red cell survival increased in parallel as the amount of cell-bound antibody decreased. The rise in serum antibody might likewise be explained by sudden release of stored antibody from lymphocytes or other cells. This effect of prednisone appears to be seen only with high doses of the drug and probably accounts for the rapid, early amelioration of hemolysis after the institution of therapy. The basis of this effect is the subject for further investigation. 
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